EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients

Yue Sun iD, Gelan Zhu iD, Hua Zhong iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14187 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Yue Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Flow Cytometry, Disease Management. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Shanghai Shenkang Hospital Development Center, Shanghai Municipal Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi‐parameter flow cytometry (MFC), polymerase chain reaction (PCR), and next‐generation sequencing (NGS) are commonly employed techniques for identifying MRD. In the context of AML, patients are frequently monitored for measurable residual disease via multi‐parameter flow cytometry (MFC‐MRD). In order to explore recent advancements in AML and MRD diagnosis, an extensive search of the PubMed database was conducted, focusing on relevant research in the past 20 years. This review aims to examine various MRD monitoring methods, the optimal time points for assessment, as well as different specimen types used. Additionally, it underscores the significance of MFC‐MRD assessment in guiding the treatment of elderly AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteFlow CytometryDisease ManagementHumansAgedHigh-Throughput Nucleotide SequencingPrognosisImmunophenotypingAge Factors

Stichwörter der Autor:innen

acute myeloblastic leukemiaage related clonal hematopoiesisflow cytofluorometryminimal residual diseasestem cell transplantation, hematopoietic

Autor:innen und Institutionen

  • Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.

ORCID-Profile: Yue Sun, Gelan Zhu, Hua Zhong

Förderung

  • Shanghai Shenkang Hospital Development Center
  • Shanghai Municipal Hospital Development Center

Zitieren

APA

Sun, Y., Zhu, G., & Zhong, H. (2024). Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients. European Journal of Haematology. https://doi.org/10.1111/ejh.14187

Vancouver

Sun Y, Zhu G, Zhong H. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients. European Journal of Haematology. 2024. doi:10.1111/ejh.14187

BibTeX
@article{Sun2024,
  author = {Sun, Yue and Zhu, Gelan and Zhong, Hua},
  title = {Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14187}
}
Kostenlos starten →